Positive outcome of the pivotal Phase III study with PQ Grass 27600 SU, a modified
grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine
(MCT) and Monophosphoryl Lipid A (MPL) as adjuvant system
Authors
S Zielen
1
Dept Children and Adolescents; Allergology, Pulmonology and Cystic Fibrosis, Goethe
University
J Bernstein
2
University of Cincinnati; Bernstein Clinical Research Center, LLC
U Berger
3
University of Innsbruck, Department of Botany
M Berger
4
Wiener Gesundheitsverbund, Klinik Landstraße, Hals-Nasen-Ohren-Abteilung
R Mösges
5
Institute of Medical Statistics and Computational Biology, Faculty of Medicine
M Cuevas
8
Allergy Therapeutics
M Shamji
6
Immunomodulation & Tolerance Group, Dept National Heart and Lung Inst, Imperial College
London
L Dubuske
7
Div. Allergy and Immunology, Department of Internal Medicine, George Washington Univ
Hospital
